Taysha Gene Therapies to End Development of TSHA-120 After FDA Feedback
By Ben Glickman
Taysha Gene Therapies will discontinue development of its TSHA-120 program to treat giant axonal neuropathy after receiving feedback from the U.S. Food and Drug Administration.
The Dallas-based gene-therapy developer said that it had received Type C meeting feedback from the FDA. Chief Executive Sean Nolan said that the feedback pointed out "challenges related to the feasibility of the study designs" to support approval by the FDA.
The company will pursue external strategic options for TSHA-120, which is meant to extend Taysha's cash runway into the fourth quarter of 2025.
Taysha said that Astellas Gene Therapy had decided not to exercise its exclusive license option under a prior agreement between the two companies.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
September 19, 2023 16:37 ET (20:37 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now